Rothschild & Co Redburn initiated coverage of MoonLake Immunotherapeutics (MLTX) with a Neutral rating and $65 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics: Promising Phase 3 Trials and Market Potential for Sonelokimab
- MoonLake Immunotherapeutics: Strategic Positioning and Promising Clinical Developments Drive Buy Rating
- Stat’s Feuerstein says ‘no imminent acquisition’ of MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics Elects Directors at AGM
- MoonLake Immunotherapeutics: Strong Acquisition Interest and Promising Product Pipeline Drive Buy Rating